You can find my blog at www.mariakonovalenko.wordpress.com
You can find my blog at www.mariakonovalenko.wordpress.com
Posted at 01:20 PM | Permalink | Comments (0)
The authors are: Michael J. Rae, Robert N. Butler, Judith Campisi, Aubrey D. N. J. de Grey, Caleb E. Finch, Michael Gough, George M. Martin, Jan Vijg, Kevin M. Perrott, Barbara J. Logan.
The article was published on July, 14. The authors advocate that funding of scientific research is substantailly increased and interventions for aging humans are developed.
Progressive accumulation of aging damage is the physiological cause of numerous age-related pathologies, loss of functionality and increased mortality. Aging places an unprecedented economic and social challenges, as the global increase of medical costs and decreased national workforce's ability. Interventions to to retard, arrest, and even reverse aging damage need to be developed in order to prevent our society from experiencing these catastrophes.
I'd like to pay more attention to the particular research directions. To my mind the authors focused on some really important areas. I put them here in a form of a list, I guess it's better if one adds numbers.
1. Loss of Proliferative Homeostasis: embraces
1.1. age-related hyperplasia (including excessive proliferation of osteoclasts, interstitial fibrosis, and, above all, cancer),
1.2. loss of tissue renewal through stem cell attrition (due, e.g., to cellular senescence, apoptosis)
or atrophy (from systemic endocrinological and signaling changes)
1.3. as well as aberrant differentiation (e.g., accumulation of mesenchymal adipocyte-like cells in aged
tissues, incomplete myocyte development in skeletal muscle, osteoblast-like
differentiation of calcifying vascular smooth muscle cells, adipogenic transformation of
thymic stromal cells in thymic involution, etc)
Continue reading "Politically important article in Science Translational Medicine" »
Posted at 02:34 PM | Permalink | Comments (3)
Technorati Tags: healthspan increase, life extension, policy, research agenda, research funding, scientific article
I am always very pleased to see new research results in the "misterious" area of neurophysiology of aging. One of the lastest is published in the July 28 issue of the Journal of Neuroscience. A group of scientists from the Washington University School of Medicine found that the mediator of diet restriction, SIRT1, helps mice survive when the food is scarce.
Researchers compared two groups of mice, one that had elevated levels of SIRT1 in the brain, called BRASTO, and a SIRT1-deficient group. BRASTO mice were much more active after fasting, also they were able to maintain their body temperature. Investigators link these findings to the role of SIRT1 in the hpothalamus region of the brain. During diet restriction SIRT1 enhanced the production of a specific neural receptor in the hypothalamus involved in regulating metabolic rate, food intake and insulin sensitivity.
This is the evidence of an indirect link between SIRT1 expression in the brain and life extension. Since SIRT1 seems to be one of the key mediators of responce to diet restriction, and diet restriction was shown to increase lifespan in different model animals, SIRT1 may contribute to life extension effect of low calorie diet. More information can be found here.
Posted at 02:15 PM | Permalink | Comments (2)
Technorati Tags: brain, BRASTO, diet restriction, hpothalamus, life extension, mice, neuroscience, SIRT1, sirtuins
I have just come back from a totally great vacation in Turkey. I stayed at the Adam&Eve hotel in Belek. Had a wonderful time!
Now I'm going to the Systems Biology of Aging meeting in Newcastle, UK.
Posted at 12:02 PM | Permalink | Comments (5)
Technorati Tags: adam and eve, hotel, life, meaning of life, systems biology of aging, turkey, vacation
Why is it actually that life extension research is funded so insufficiently? Well, here is why. Of course, there are people who have money. And they're not averse to thinking about scientific research. It may turn out to be quite a useful thing. Moreover, one can make money out of it. Yes, these people would love to have a magnificent innovation, a biotech company. They tell the scientists: “Bring us the business plan! – We’ll consider it.” And here’s the thing… If the idea is truly new, there is no business plan; there’s not even a guaranteed result. The planning of the innovative work itself turns out to be an extremely hard and expensive task. And a good scientist is always busy, so he cannot really create beautiful presentations, and he also has absolutely no idea that more scientists need to be engaged in this kind of work, and that the main costs will be the organizational ones. So, this means that the investor wants some tremendous work from the scientist and only then would he make a decision about the money. That is why large organizations that announce grants receive bad proposals, because nobody invests in the creation of the project proposal, or because the proposal is some really old stuff that, for some reason, makes an impression.
Just imagine, an investor wants a huge, 600,000 square foot, shopping center to be built, and he tells the architects: “Well, guys, just give me a project with all the services, utilities, calculations, and logistics, and then I’ll see whether or not to finance the construction and your work or not.” The architects would faint after hearing such a wonderful proposal. Or, they would give the investor some old project that they have already done, but, in our case, haven’t been able to create an innovation.
What needs to be done? First of all, one should ask the scientists to write proposals for money. He should also understand that a lot of what they’d write just wouldn’t be satisfactory. There’s this thing here: a sucessful scientist is overwhelmed with work for the next 3 years, and he wouldn’t stand in the line in front of the investor’s door. One has to find the scientist and persuade him to cooperate. Then comes the reviewing part (it’s another story about how to get impartiality). Then comes the choice of the project. And still, it will be risky. Here I'd like to say a couple of words about the necessety of a complex and systems approach, but maybe another time.
Posted at 02:41 AM | Permalink | Comments (0)
Technorati Tags: biotech, block, blocking point, business plan, investment, investment project, reseach funding, research proposal
The H+ Summit took place in Boston on June 12-13 at the Harward University Science Center. Here are some photos that I took at the meeting. Above pictured are the organizers David Orban and Alex Lightman introducing Andrea Kuszewski, who worked on enhancing the intelligence of the audience.
Posted at 11:22 PM | Permalink | Comments (0)
Technorati Tags: alex lightman, aubrey de grey, boston, conference, david orban, H+, H+ Summit, harward university, hplus, hplussummit, immortalism, intelligence, meeting, ray kurzweil, technology development, transhumanism
Posted at 01:05 AM | Permalink | Comments (2)
Technorati Tags: anti-eptropy process, artificial intelligence, future, human potential, immortalism, improvement, intellect, life extension, possibility, progress, radical life extension, research, science, strategy, Technological Singularity, technology, transhumanism, up grade
For now all that we have is negligible funding of evolutionary-comparative biology of aging. Moreover, previously obtained results are put into cold storage.
In 1962 George Sacher began laboratory breeding of wild-caught house mice (Mus musculus) and white-footed mice (Peromyscus leucopus) trapped near the Argonne Laboratory site in northeast Illinois. The maximal lifespan of the white-footed mouse turned out to be more than 8 years, contrary to 3,5 years in either wild-caught or laboratory house mice. Sacher’s laboratory publiched about a dozen papers comparing house and white-footed mice, as did Ron Hart’s laboratory in the National Center for Toxicological Research.
There's no need to say that George Sacher was given grants mostly for works in the area of radiological protection, and aging research was mostly funded by means of the lab's own resources.
Since the beginning of the 1980s research was just middling, but still something was found out.
Below are some data from the works of Ungvary et al. and Labinskyy et al. Basicly this table shows the major known differences between the species. The autors claim that these data correspond with the oxidative stress theory of aging.
Still a lot of questions can be addressed to the white-footed mouse. For example, what is the destinction in the stress resistance mechanisms? What's with its regeneration capacity? What if we compare it with the naked mole rat? And here comes the main question in Biogerontology. Why is the research into the fundamental mechanisms of aging so scarcely funded?
Here is the updated edition of the Roadmap to Regenerative Medicine; the first one can be found here. Cell therapy and tissue engineering are described in more detail, than the rest of the scientific issues. I welcome everybody to take a look and add what's missing and/or change what's wrong. I'd also like to note that the organizational issues aren't described at all, but this is probably the most important part of the roadmap. There should be an implementational plan of how exactly the Roadmap should work included in the organizational part. To do that, we need to address the specialists in the given fields.
But at least for now the question is - what's missing in the scientific part?
You can download the Roadmap here.
Here
are the main questions in the Biology of Aging. I suggest that the specialists
should extend the list of questions. And maybe, formulate the problems in more
detail. Everybody is welcome to express their opinion and suggest some
answers.